Related Experiment Video

Updated: May 18, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Tivozanib: current status and future directions in the treatment of solid tumors

Sumanta K Pal1, Paulo G Bergerot, Robert A Figlin

  • 1City of Hope Comprehensive Cancer Center, Department of Medical Oncology & Experimental Therapeutics, 1500 East Duarte Road, Duarte, CA 91010, USA. spal@coh.org

Expert Opinion on Investigational Drugs
|September 28, 2012
PubMed
Abstract

Insights

Tivozanib, a vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI), shows potential in metastatic renal cell carcinoma (mRCC). Emerging combination studies and biomarker assessments may define its role among VEGF-TKIs.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Tivozanib is a novel tyrosine kinase inhibitor (TKI).
  • It potently inhibits vascular endothelial growth factor (VEGF) receptors -1, -2, and -3 at nanomolar concentrations.

Purpose of the Study:

  • To review the development pathway of tivozanib.
  • To discuss its clinical and translational data.
  • To identify future opportunities for this agent.

Main Methods:

  • Comprehensive literature search of MEDLINE and American Society of Clinical Oncology abstracts.
  • Review of pre-clinical studies, Phase I assessment in advanced solid tumors.
  • Analysis of combination studies, including cytotoxic therapy pairings.
  • Detailed description of Phase II and Phase III studies in metastatic renal cell carcinoma (mRCC).

Main Results:

  • Tivozanib demonstrates activity in advanced solid tumors.
  • Combination studies explore its efficacy with cytotoxic agents in colorectal and breast cancers.
  • Phase II and III studies assess its role in mRCC.

Conclusions:

  • Tivozanib faces competition in the mRCC therapeutic landscape.
  • Emerging combination studies and biomarker assessments are crucial for its differentiation.
  • The review provides insights into tivozanib's development and future potential.

More Related Videos

Screening Ion Channels in Cancer Cells06:19

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...